Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/162610
Full metadata record
DC FieldValueLanguage
dc.contributor.authorIbáñez-Sanz, Gemma-
dc.contributor.authorGuinó, Elisabet-
dc.contributor.authorPontes, Caridad-
dc.contributor.authorQuijada Manuitt, M. Angeles-
dc.contributor.authorde la Peña-Negro, LuisaC-
dc.contributor.authorAragón, María-
dc.contributor.authorDomínguez, Marga-
dc.contributor.authorRodríguez Alonso, Lorena-
dc.contributor.authorBlasco, Alex-
dc.contributor.authorGarcía-Rodríguez, Ana-
dc.contributor.authorMorros Pedrós, Rosa-
dc.contributor.authorMoreno Aguado, Víctor-
dc.date.accessioned2020-05-27T11:31:01Z-
dc.date.available2020-05-27T11:31:01Z-
dc.date.issued2019-09-19-
dc.identifier.issn2045-2322-
dc.identifier.urihttp://hdl.handle.net/2445/162610-
dc.description.abstractThere is extensive debate regarding the protective effect of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) on colorectal cancer (CRC). We aimed to assess the association between CRC risk and exposure to statins using a large cohort with prescription data. We carried out a case-control study in Catalonia using the System for Development of Primary Care Research (SIDIAP) database that recorded patient diseases history and linked data on reimbursed medication. The study included 25 811 cases with an incident diagnosis of CRC between 2010 and 2015 and 129 117 frequency-matched controls. Subjects were classified as exposed to statins if they had ever been dispensed statins. Analysis considering mean daily defined dose, cumulative duration and type of statin were performed. Overall, 66 372 subjects (43%) were exposed to statins. There was no significant decrease of CRC risk associated to any statin exposure (OR = 0.98; 95% CI: 0.95-1.01). Only in the stratified analysis by location a reduction of risk for rectal cancer was observed associated to statin exposure (OR = 0.87; 95% CI: 0.81-0.92). This study does not support an overall protective effect of statins in CRC, but a protective association with rectal cancer merits further research.-
dc.format.extent8 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherNature Publishing Group-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1038/s41598-019-49877-5-
dc.relation.ispartofScientific Reports, 2019, vol. 9, p. 13560-
dc.relation.urihttps://doi.org/10.1038/s41598-019-49877-5-
dc.rightscc-by (c) Ibáñez-Sanz, Gemma et al., 2019-
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es-
dc.subject.classificationCàncer colorectal-
dc.subject.classificationFarmacologia-
dc.subject.otherColorectal cancer-
dc.subject.otherPharmacology-
dc.titleStatin use and the risk of colorectal cancer in a population-based electronic health records study-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec698690-
dc.date.updated2020-05-27T11:31:01Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
Appears in Collections:Articles publicats en revistes (Ciències Clíniques)

Files in This Item:
File Description SizeFormat 
698690.pdf953.34 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons